Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Witkin

Showing results (281-290 of 321) with videos related to

Pageof 33
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 6, 2008
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophreniaW Y Chan, D L McKinzie, S Bose, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 3, 2019
Erratum: A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical StudiesAnke Post, Trevor S Smart, Judith Krikke-Workel, et al.
Pharmacology, Biochemistry, and Behavior|January 18, 2022
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disordersJeffrey M Witkin, Arnold Lippa, Jodi L Smith, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 21, 2015
A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical StudiesAnke Post, Trevor S Smart, Judith Krikke-Workel, et al.
CNS & Neurological Disorders Drug Targets|March 16, 2017
Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in MiceAnna E Martin, Douglas A Schober, Alexander Nikolayev, et al.
Brain Research|August 2, 2019
The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81Jeffrey M Witkin, Xingjie Ping, Rok Cerne, et al.
Psychopharmacology|March 27, 2007
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disordersLinda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, et al.
Pharmacology, Biochemistry, and Behavior|April 27, 2017
Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABA<sub>A</sub> receptorsJ M Witkin, R Cerne, M Wakulchik, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 17, 2014
Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent modelsR Zwart, E Sher, X Ping, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 5, 2014
M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamineJ M Witkin, C Overshiner, X Li, et al.
Pageof 33

Showing results (281-290 of 321) with videos related to

Sort By:
Pageof 33
Proceedings of the National Academy of Sciences of the United States of America|August 6, 2008
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophreniaW Y Chan, D L McKinzie, S Bose, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 3, 2019
Erratum: A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical StudiesAnke Post, Trevor S Smart, Judith Krikke-Workel, et al.
Pharmacology, Biochemistry, and Behavior|January 18, 2022
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disordersJeffrey M Witkin, Arnold Lippa, Jodi L Smith, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 21, 2015
A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical StudiesAnke Post, Trevor S Smart, Judith Krikke-Workel, et al.
CNS & Neurological Disorders Drug Targets|March 16, 2017
Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in MiceAnna E Martin, Douglas A Schober, Alexander Nikolayev, et al.
Brain Research|August 2, 2019
The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81Jeffrey M Witkin, Xingjie Ping, Rok Cerne, et al.
Psychopharmacology|March 27, 2007
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disordersLinda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, et al.
Pharmacology, Biochemistry, and Behavior|April 27, 2017
Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABA<sub>A</sub> receptorsJ M Witkin, R Cerne, M Wakulchik, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 17, 2014
Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent modelsR Zwart, E Sher, X Ping, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 5, 2014
M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamineJ M Witkin, C Overshiner, X Li, et al.
Pageof 33